Artera’s multimodal artificial intelligence (MMAI) platform has demonstrated notable prognostic value in prostate and early-stage breast cancer. Studies presented at ASCO 2024 highlighted the platform’s ability to provide personalized therapy recommendations based on image analysis of hematoxylin and eosin (H&E)-stained pathology slides.

Traditionally, personalized cancer treatment plans required multiple tests, which can be costly and inefficient. Artera’s AI-enabled algorithms overcome this challenge by extracting valuable information from digitized H&E slides. This analysis aids clinicians and patients in making informed treatment decisions.

According to Trevor Royce, Senior Medical Director at Artera, the platform’s versatility in analyzing different patient cohorts suggests the reliability of H&E slide analysis in tailoring treatment.

Andre Esteva, CEO of Artera, emphasizes the groundbreaking potential of this approach. He highlights how AI and image analysis can accelerate innovation and advance cancer care.

Artera’s model leverages clinical data and pathology slide images to provide actionable insights. By combining these sources, Artera aims to:

• Enhance treatment personalization
• Minimize unnecessary treatment side effects
• Increase confidence in decision-making

The platform’s scalability allows for widespread application, facilitating the development of novel biomarkers and tailored treatment strategies for various cancer stages. As treatment options expand, individualizing patient care becomes increasingly important. Artera’s multimodal AI platform is poised to revolutionize precision oncology, providing patients with optimal and informed treatment journeys.

Source link: http://www.businesswire.com/news/home/20240531063105/en/Artera-Announces-Three-Presentations-at-ASCO-2024-That-Demonstrate-the-Reliability-and-Depth-of-its-AI-Cancer-Platform

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.